Actively Recruiting
Study to Assess Safety, Tolerability, and Metabolism of NNC0705-0002 in Healthy Adults with Single and Multiple Oral Doses
Led by Novo Nordisk A/S · Updated on 2026-09-30
112
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new medicine called NNC0705-0002, which is being developed for conditions where inflammation might affect heart and metabolic health. This early phase study focuses on assessing the safety, how well the medicine is tolerated, how it moves through and affects the body, and its metabolism in healthy adults. The study involves healthy volunteers aged 18 to 55. Participants will receive either NNC0705-0002 or a matching placebo in various ways as a single ascending dose, multiple ascending doses, or under fed and fasted conditions. The medicine and placebo are given orally in capsule form. Treatment schedules vary depending on the part of the study, with dosing designed to explore different conditions and amounts. The study lasts up to about 7 weeks including screening, treatment, and follow-up visits. During the study, participants will have regular health assessments including medical history reviews, physical exams, vital sign checks, electrocardiograms, and laboratory tests. Researchers will monitor for any side effects and measure how much of the medicine is in the blood over time and how it is processed and excreted. Safety is closely observed from dosing through the follow-up period to understand the medicines effects and metabolism.
CONDITIONS
Brief Title
A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here